TGTX
TG Therapeutics, Inc.30.79
-0.62-1.97%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
4.89BP/E (TTM)
11.12Basic EPS (TTM)
2.77Dividend Yield
0%Recent Filings
8-K
BRIUMVI revenue soars
TG Therapeutics reported third-quarter 2025 total revenue of $161.7 million, driven by BRIUMVI U.S. net sales of $152.9 million, up 84% from last year. The company raised its full-year BRIUMVI U.S. guidance to $585 million, reflecting robust demand, while advancing Phase 3 trials for subcutaneous ublituximab and simplified IV dosing. It completed a $100 million share repurchase and authorized another. Cash stands at $178.3 million, sufficient for operations. Revenue momentum surges.
10-Q
Q2 FY2025 results
TG Therapeutics posted strong Q2 results, with net product revenue from BRIUMVI surging 91% y/y to $138.8M, driving total revenue up 92% y/y to $141.1M and flipping operating income positive at $34.8M versus $8.8M last year. Gross margin held steady around 87%, while diluted EPS climbed to $0.17 from $0.04, reconciling neatly with 162.6M weighted shares. YTD revenue doubled to $262.0M, but R&D spend jumped 81% y/y to $78.1M on pipeline pushes like azer-cel. Cash and equivalents dipped to $129.1M amid $21.3M operating outflow, offset by $250M term loan maturing 2029 at variable rates; free cash flow not disclosed in the 10-Q. Revenue hinges on BRIUMVI uptake. Yet competition in MS therapies looms large.
8-K
BRIUMVI revenue surges, guidance raised
TG Therapeutics reported Q2 2025 total revenue of $141.1 million, driven by BRIUMVI U.S. net sales of $138.8 million, up 91% year-over-year and 16% from Q1. The company raised its full-year BRIUMVI guidance to $570-$575 million, reflecting strong MS market uptake and international expansion via Neuraxpharm approvals in Europe, UK, Switzerland, and Australia. Net income hit $28.2 million, while R&D and SG&A costs rose on subcutaneous development and commercialization efforts. BRIUMVI's pipeline advances, including ENHANCE trial enrollment, position it for class leadership, but sustained sales momentum remains key amid competition.
8-K
Annual meeting elects directors
TG Therapeutics held its 2025 Annual Meeting on June 12, electing six directors amid mixed support—Michael S. Weiss secured 85.55% approval, while Sagar Lonial, MD, garnered just 54.12%. Shareholders ratified KPMG as auditors with overwhelming 99.6% backing and approved executive compensation on a slim 47.9% majority. The board's push to expand the 2022 Incentive Plan by 5 million shares passed handily at 92.8%. Strong governance signals stability, yet director pushback hints at scrutiny.
10-Q
Q1 FY2025 results
TG Therapeutics swung to profitability in Q1 2025, posting $120.9M in total revenue—a 90% y/y surge driven by $119.7M from BRIUMVI sales, up from $50.5M last year, while costs climbed to $112.2M amid ramped-up R&D and SG&A. Gross margin held steady at 87.0%, yielding $8.6M operating income versus a $9.3M loss before; net income hit $5.1M or $0.03 diluted EPS on 162.8M shares, reconciling cleanly with no anti-dilution flags. Cash burn eased to $28.7M from operations, leaving $276.2M in liquidity against $244.7M non-current debt maturing 2029 at variable rates tied to sales milestones. BRIUMVI's U.S. momentum persists, bolstered by ex-U.S. royalties from Neuraxpharm. Yet biosimilar competition looms large.
IPO
Employees
Sector
Industry
BCTX
BriaCell Therapeutics Corp.
8.70-0.28
BIIB
Biogen Inc.
171.50-4.24
FBRX
Forte Biosciences, Inc.
23.27+1.31
GLPG
Galapagos NV
31.08-0.03
IMTX
Immatics N.V.
10.09+0.11
MGNX
MacroGenics, Inc.
1.35-0.02
MRKR
Marker Therapeutics, Inc.
1.27-0.12
NRIX
Nurix Therapeutics, Inc.
18.84-0.17
ONC
BeOne Medicines Ltd.
304.31-6.36
TOVX
Theriva Biologics, Inc.
0.21+0.01